

ANTIBODY/TARGETED-DRUG CONJUGATES

22-24 March 2017, LUMC, Leiden, The Netherlands

FINAL ORAL PROGRAMME ATDC 2017

SCIENTIFIC ADVISORY PANEL

- John A. Flygare (*Merck Inc., USA*)
Greg Bleck (*Catalent Pharma Solutions, Somerset, New Jersey, USA*)
Victor Goldmacher (*Cancer Targeting Solutions LLC, USA*)
John Lambert (*ImmunoGen Inc., Waltham, Massachusetts, USA*)
Roger R. Beerli (*NBE-Therapeutics LLC, Basel, Switzerland*)
Michael Firer (*Ariel University, Ariel, Israel*)
Alain Beck (*Centre d'Immunologie Pierre Fabre, St Julien-en-Genevois, France*)
Philip Howard (*MedImmune/Spirogen Ltd, London, UK*)
Peter Hofland (*InPress Media Group, Phoenix, Arizona, USA*)
David Rabuka (*Catalent Pharma Solutions, Somerset, New Jersey, USA*)
Peter Park (*Bicycle Therapeutics Inc., Cambridge, Massachusetts, USA*)
Hendrik Jan Houthoff (*LinXis Pharmaceuticals BV, Amsterdam, The Netherlands*)
Deyarina Gonzalez (*Swansea University Medical School, Swansea, Wales, UK*)
Chris Scott (*Queen's University Belfast, Belfast, UK*)
Ulrich Storz (*Michalski Hattermann & Partners, Dusseldorf, Germany*)
Aad van de Leur (*Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands*)
Floris van Delft (*Synaffix BV, Oss, The Netherlands*)

Genentech
A Member of the Roche Group

Pfizer Oncology

Catalent
BIOLOGICS

IMMUNOGEN, INC.

SUTRO
BIOPHARMA

NatureGeneTherapy
Gene-based vaccines

aldevron

ON drugDELIVERY

NBE therapeutics

LinXis

ADC REVIEW
JOURNAL OF ANTIBODY-DRUG CONJUGATES

Cancer Targeting Solutions Consulting, LLC

Onco'Zine
The International Oncology Network

Lonza

GENOVS

08.00
Arrival & Registration

09.00
Opening Remarks

SESSION 1: OPENING PLENARY SESSION

Moderator: John A. Flygare
(Merck Inc., USA)

09.00-09.45

'Biology and engineering of Cow ultralong CDR3 antibodies'

Vaughn Smider
(Sevion Therapeutics, San Diego, California, USA)

09.45-10.30

'The development of antibody pyrrolobenzodiazepine conjugates'

Philip Howard
(MedImmune/Spirogen Ltd, London, UK)

10.30-11.00

Coffee Break & Posters

SESSION 2: PLENARY

Moderator: Roger R. Beerli
(NBE-Therapeutics Ltd., Basel, Switzerland)

11.00-11.45

'Pre-clinical development of a Fit3 specific ADC (AGS62P1) for the treatment of acute myeloid leukemia (AML) utilizing site specific conjugation and a novel, potent, tubulin inhibiting payload'

Kendall Morrison
(Agensys Inc., Santa Monica, California, USA)

11.45-12.30

'Update on mirvetuximab soravtansine and ImmunoGen's growing ADC pipeline'

John Lambert
(ImmunoGen Inc., Waltham, Massachusetts, USA)

12.30-12.45

Moderator-led Session Discussion

12.45-14.00

Lunch Break & Posters

SESSION 3: CONJUGATION

Moderator: John Lambert
(ImmunoGen Inc., Waltham, Massachusetts, USA)

14.00-14.30

'Development on novel bioconjugation technologies for ADCs'

Vijay Chudasama
(University College London, London, UK)

14.30-15.00

'Highly potent, anthracycline-based ADCs generated by enzymatic, site-specific conjugation'

Roger R. Beerli
(NBE-Therapeutics Ltd., Basel, Switzerland)

15.00-15.30

'Moving a chemo-enzymatic protein conjugation technology from benchtop to large scale production'

Gregory Bleck
(Catalent Pharma Solutions, Somerset, New Jersey, USA)

15.30-15.45

Moderator-led Session Discussion

15.45-16.15

Tea Break & Posters

SESSION 4: ANTIBODY DRUG CONJUGATES

Moderator: David Rabuka
(Catalent Pharma Solutions, Somerset, New Jersey, USA)

16.15-16.45

'A novel platinum (II)-based bifunctional ADC linker benchmarked using 89Zr-Desferal and Auristatin F conjugated Trastuzumab'

Eugen Merkul
(LinXis Pharmaceuticals, Amsterdam, The Netherlands)

16.45-17.15

'Enabling better Antibody Drug Conjugates'

Campbell Bunce and George Badescu
(Abzena PLC, Cambridge, UK)

17.15-17.45

'Glycan-conjugated ADCs come with significantly expanded therapeutic index compared to both marketed ADCs'

Floris van Delft, Brian Janssen, Inge Hurkmans, Remon van Geel, Jorge Verkade, Jorin Hoogenboom, Marloes, Wijdeven and Sander van Berkel
(Synaffix BV, Oss, The Netherlands)

17.45-18.00

Moderator-led Session Discussion

18.00-19.00

ATDC 2017 Welcome Drinks Reception & Posters

**SESSION 5:
NOVEL ALTERNATIVES**

Moderator: Kendall Morrison
(Genzyme Inc., Santa Monica, California, USA)

09.00-09.45

'Exploring novel bioconjugate applications using SMARTag technology'

David Rabuka
(Catalent Pharma Solutions, Somerset, New Jersey, USA)

09.45-10.15

'Non-internalizing small molecule-drug conjugates for the treatment of solid tumors'

Samuele Cazzamalli, Alberto Dal Corso and Dario Neri
(Institute of Pharmaceutical Sciences, ETH Zurich, Switzerland)

10.15-10.45

'Aspects of targeted therapeutics'

Deryk T. Loo
(MacroGenics West, South San Francisco, California, USA)

10.45-11.15

Coffee Break & Posters

**SESSION 6:
ANTIBODY-DRUG CONJUGATES**

Moderator: Victor Goldmacher
(Cancer Targeting Solutions LLC, USA)

11.15-12.00

'New chemical linkers for antibody-drug conjugates'

Thomas Pillow
(Genentech, South San Francisco, California, USA)

12.00-12.30

'Non-cleavable pyrrolobenzodiazepine antibody-drug conjugates'

Stephen Gregson
(Spirogen-MedImmune, QMB Innovation Centre, London, UK)

12.30-13.00

'Radiochemistry and immuno-PET in ADC development: Taking the fast lane'

Danielle Vugts
(VUMC, Amsterdam, The Netherlands)

13.00-14.00

Lunch Break & Posters

**SESSION 7:
CANCER & TARGETTING**

Moderator: Philip Howard
(MedImmune/Spirogen Ltd, London, UK)

14.00-14.30

'Antibody-drug conjugates for cancer therapy: Critical parameters'

Victor Goldmacher
(Cancer Targeting Solutions LLC, USA)

14.30-15.00

'Development of the ADC's for application in gynaecological cancers'

Deyarina Gonzalez and Steven Conlan
(Swansea University Medical School, Swansea, Wales, UK)

15.00-15.30

'Efficient payload delivery by a bispecific antibody-drug conjugate targeting HER2 and CD63'

Bart ECG de Goeij¹, Tom Vink¹, Hendrik ten Napel¹, Esther CW Breij¹, David Satijn¹, Richard Wubbolts², David Miao³ and Paul W.H.I. Parren^{1,4,5}
(¹ Genmab, Utrecht, The Netherlands; ² Utrecht University, Utrecht, The Netherlands; ³ Concortis Biosystems Corp., San Diego, USA; ⁴ University of Southern Denmark, Odense, Denmark; ⁵ Leiden University Medical Center, Leiden, The Netherlands)

15.30-15.45

Tea Break & Posters

15.45-16.15

'Sweet delivery of the bitter: Using carbohydrate-targeting antibodies for tumor-specific delivery of cytotoxic drugs'

Lars Stockl
(GlycoTope GmbH, Berlin, Germany)

16.15-16.45

'HDP-101 A BCMA-targeted Amanitin-based ADC'

Andreas Pahl
(Heidelberg Pharma, Ladenberg, Germany)

16.45-17.00

Moderator-led Session Discussion

**SESSION 8:
PANEL DISCUSSION**

17.00-17.20

'Antibody-drug conjugates: IP considerations'

Ulrich Storz
(Michalski Hüttermann Patent Attorneys, Düsseldorf, Germany)

17.20-17.40

'IS everything already invented?'

Anwyn Dullaart
(European Patent Office, Rijswijk, The Netherlands)

17.40

Discussion

**SESSION 9:
DEVELOPMENT**

Moderator: Christopher Scott

(Queen's University of Belfast, Belfast, Northern Ireland, UK)

09.00-09.45

'Development of nano-conjugates as novel therapeutics'

Christopher Scott

(Queen's University of Belfast, Belfast, Northern Ireland, UK)

09.45-10.15

'Manufacturing of SYD985, a duocarmycin-based ADC'

Aad van de Leur

(Synthon Biopharmaceuticals BV, Nijmegen, The Netherlands)

10.15-10.45

'Optimized methods for site-specific antibody drug conjugations avoiding cross-linked byproducts'

Amy Han

(Regeneron Inc., Tarrytown, New York, USA)

10.45-11.15

'Scaling-up and manufacturing antibody-drug conjugates'

Laurent Ducry *(Lonza AG, Visp, Switzerland)*

11.15-11.30

Coffee Break & Posters

**SESSION 10:
ANTIBODY DRUG CONJUGATES**

Moderator: Hendrick Jan Houthoff

(LinXis Pharmaceuticals, Amsterdam, The Netherlands)

11.30-12.00

'TG-IPH Technology for site-specific conjugation'

Delphine Bregeon and Florence L'Hospice

(Innate-Pharma S.A. Marseille, France)

12.00-12.15

POSTER 101

'Site-specific and quantitative conjugation of functional groups to antibody N-glycans using the novel GlyCLICK technology'

H. Toftvall¹, H. Nyhlén¹, M. Widgren Sandberg¹, B. Agnew² and F. Olsson¹

(¹ Genovis AB, Lund, Sweden; ² Thermo Fisher Scientific, Eugene, Oregon, USA)

12.15-12.30

POSTER 102

'Chemical cross-linking strategies for the construction of homogeneous protein bioconjugates'

Nafsika Forte, Kerry Chester, Vijay Chudasama and James Baker

(UCL Chemistry Department, London, UK; UCL Cancer Institute, London, UK)

12.30-12.45

POSTER 103

'Pyridazinediones: Highly versatile chemical linkers for bioconjugation'

Daniel A. Richards¹, Antoine Maruani¹, Maximillian T. Lee¹, Joao C. F. Nogueira¹, Michelle Greene², Christopher Scott² and Vijay Chudasama¹

(¹ University College London, London, UK; ² Queen's University Belfast, Belfast, Northern Ireland, UK)

12.45-13.00

POSTER 104

'Dual site-specifically modified antibodies using solid-phase immobilized microbial transglutaminase'

Philipp R. Spycher¹, Christian A. Amann¹, Jöri E. Wehrmüller¹, David R. Hurwitz¹, Olivier Kreis¹, Daniel Messmer², Andreas Ritler^{1,3}, Andreas Küchler², Alain Blanc¹, Martin Behé¹, Peter Walde² and Roger Schibli^{1,4}

(¹ Paul Scherrer Institute, Villigen PSI, Switzerland; ² Laboratory of Polymer Chemistry, Department of Materials, ³ Laboratory of Organic Chemistry and ⁴ Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zurich, Zurich, Switzerland)

Lunch Break & Departure

POSTER 105

'Antibody Drug Conjugates for gynaecological cancers'

Belen Pan Castillo, R. Steve Conlan and Deyarina Gonzalez

(Swansea University Medical School, Swansea University, Swansea, Wales, UK)

* This final programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.